Silexion Therapeutics

SLXNNasdaq Israel Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$2.188 M

$0.14 -6.32%

Close of 6 Nov 2026

As of 6 Nov 2026, Silexion Therapeutics (SLXN) has a market capitalization of $2.19M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$11.9M

Loss-making

Shares outstanding

5,560,256

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Other share classes

Silexion Therapeutics lists more than one class of stock. Company figures above cover all classes combined.

SLXNW

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#159Tessera Defense & Homeland SecurityHLSQ$3.22M
#160VivoSim LabsVIVS$2.41M
#161Calidi BiotherapeuticsCLDI$2.32M
#162Silexion TherapeuticsSLXN$2.19M
#163Scinai ImmunotherapeuticsSCNI$1.21M

What if Silexion Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$1,856,038

Per share 12,907,082× higher

Bitcoin $1.53T

$100,427.00

Per share 698,380× higher

Apple $5.02T

$329,692.47

Per share 2,292,715× higher

Or at a round number

$5.00M $10.0M $20.0M $50.0M

Where these numbers come from

Share counts and financials for Silexion Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.